iHealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for 510K Clearance

Key Facts

“I believe that the ease of use of iHealthScreen’s AI tool will contribute to its adoption in the wider primary care community.”
AMD cases in the U.S. are expected to grow from 2.1 million to 5.4 million in the next ten years, and there is an increasing need for large-scale screening and identification of individuals who are at risk of developing late AMD.
In an interview, Dr. Bhuiyan spoke about the study and the findings: “We are encouraged by the results and believe that the new AI-based technology can diagnose early AMD in primary care settings, which enables the timely preventative measures by ophthalmologists and prevent this deterioration of vision.
“I believe that the ease of use of iHealthScreen’s AI tool will contribute to its adoption in the wider primary care community.”